Biden administration asserts power to seize drug patents in move to slash high prices

The Biden administration unveiled a new framework outlining the factors federal agencies should consider in determining whether to use march-in rights.

Previous post Binance announces Jito (JTO) listing with Seed Tag and Isolated Margin pairs
Next post U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients